PMID- 38183417
OWN - NLM
STAT- MEDLINE
DCOM- 20240313
LR  - 20240313
IS  - 1744-313X (Electronic)
IS  - 1744-3121 (Linking)
VI  - 51
IP  - 2
DP  - 2024 Apr
TI  - Reduced human leukocyte antigen mismatching is associated with more favourable 
      outcomes after unrelated donor haematopoietic stem cell transplantation.
PG  - 63-71
LID - 10.1111/iji.12651 [doi]
AB  - The patient-donor human leukocyte antigen (HLA) match remains the most important 
      prognostic factor for successful unrelated donor haematopoietic stem cell 
      transplantation (UD-HSCT). This single-centre study comprised 125 adult patients 
      with malignant haematological diseases undergoing their first UD-HSCT. The 
      primary goal of this study was to validate the impact of HLA matching on HSCT 
      outcomes, specifically at the HLA-DPB1 and HLA-DRB3/4/5 loci. A multivariable Cox 
      regression analysis with a backward selection algorithm was employed to assess 
      the associations of selected prognostic factors with outcomes after UD-HSCT. Any 
      HLA locus mismatch was found to be associated with an increased incidence of 
      grade II-IV acute graft versus host disease (aGvHD) at 100 days (p = .031; hazard 
      ratio [HR] 1.935) and 6 months (p = .004; HR 2.284) after HSCT. The results of 
      the following analyses also confirmed the strong impact of HLA-DPB1-only mismatch 
      on the incidence of grade II-IV aGvHD at 100-day (p = .006; HR 2.642) as well as 
      at 6-month (p = .007; HR 2.401) time periods. The HLA-DPB1-only mismatch was also 
      shown to be statistically significantly associated with lower relapse incidence 
      (p = .034; HR 0.333). The impact of the HLA-DRB3/4/5 mismatch on outcomes was 
      inconclusive, though the two and more HLA-DPB1 + DRB3/4/5-only mismatches showed 
      a trend towards worse outcomes than a single mismatch. Based on our findings and 
      those of more comprehensive studies, the extended HLA loci typing of patients and 
      donors is suggested to avoid unexpected HLA mismatches during the UD selection.
CI  - (c) 2024 John Wiley & Sons Ltd.
FAU - Valatkaite-Rakstiene, Beatrice
AU  - Valatkaite-Rakstiene B
AUID- ORCID: 0009-0008-7915-4702
AD  - State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
AD  - Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital 
      Santaros Klinikos, Vilnius, Lithuania.
FAU - Cekauskiene, Rita
AU  - Cekauskiene R
AD  - State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
AD  - Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital 
      Santaros Klinikos, Vilnius, Lithuania.
FAU - Zvirblis, Tadas
AU  - Zvirblis T
AD  - Department of Human and Medical Genetics, Institute of Biomedical sciences, 
      Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
FAU - Jakubauskas, Arturas
AU  - Jakubauskas A
AUID- ORCID: 0000-0002-6305-0617
AD  - State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
AD  - Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital 
      Santaros Klinikos, Vilnius, Lithuania.
LA  - eng
GR  - MIP-014/2014/Research Council of Lithuania (LMTLT)/
PT  - Journal Article
DEP - 20240106
PL  - England
TA  - Int J Immunogenet
JT  - International journal of immunogenetics
JID - 101232337
RN  - 0 (HLA-DRB3 Chains)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Unrelated Donors
MH  - HLA-DRB3 Chains
MH  - Histocompatibility Testing
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/methods
MH  - *Graft vs Host Disease/genetics
MH  - Retrospective Studies
OTO - NOTNLM
OT  - HLA matching
OT  - acute graft versus host disease
OT  - haematopoietic stem cell transplantation
OT  - unrelated donor
EDAT- 2024/01/07 06:43
MHDA- 2024/03/13 06:46
CRDT- 2024/01/06 10:53
PHST- 2023/11/08 00:00 [revised]
PHST- 2023/08/25 00:00 [received]
PHST- 2023/12/24 00:00 [accepted]
PHST- 2024/03/13 06:46 [medline]
PHST- 2024/01/07 06:43 [pubmed]
PHST- 2024/01/06 10:53 [entrez]
AID - 10.1111/iji.12651 [doi]
PST - ppublish
SO  - Int J Immunogenet. 2024 Apr;51(2):63-71. doi: 10.1111/iji.12651. Epub 2024 Jan 6.